A Review on Microbial Products and Their Perspective Application as Antimicrobial Agents

Microorganisms including actinomycetes, archaea, bacteria, fungi, yeast, and microalgae are an auspicious source of vital bioactive compounds. In this review, the existing research regarding antimicrobial molecules from microorganisms is summarized. The potential antimicrobial compounds from actinomycetes, particularly Streptomyces spp.; archaea; fungi including endophytic, filamentous, and marine-derived fungi, mushroom; and microalgae are briefly described. Furthermore, this review briefly summarizes bacteriocins, halocins, sulfolobicin, etc., that target multiple-drug resistant pathogens and considers next-generation antibiotics. This review highlights the possibility of using microorganisms as an antimicrobial resource for biotechnological, nutraceutical, and pharmaceutical applications. However, more investigations are required to isolate, separate, purify, and characterize these bioactive compounds and transfer these primary drugs into clinically approved antibiotics.


Introduction
For the last few decades, antibiotics have saved millions of lives, but the prevalence of multidrug resistance (MDR) in microbial strains, nullifying the effects of antibiotics is an expected consequence of antibiotic abuse. The emergence and prevalence of antibioticresistant microbial strains remain one of the major health issues of the 21st century, creating pressure on natural microbiota. The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are one of the greatest challenges faced by medical practices as many of them are multidrug-resistant isolates [1]. The US Centres for Disease Control and Prevention (CDC) classified the most concerning antimicrobial resistance (AMR) threats, cataloguing carbapenem-resistant P. aeruginosa, Clostridium difficile, and A. baumannii; MDR Neisseria gonorrhoeae and carbapenem-and cephalosporin-resistant Enterobacteriaceae as "urgent" threats [2], requiring urgent measures to deal with the situation. Pendleton et al. [3] provide a contemporary summary and clinically relevant information on the ES-KAPE pathogens. In contrast, a detailed description regarding the antimicrobial resistance mechanisms of ESKAPE pathogens was illustrated by Santajit and Indrawattana [1], and can be used as a tool and applied to emerging MDR pathogens. Mulani et al. [4] highlight the use of therapies, including the combination of antibiotics, bacteriophages, antimicrobial

Bacteria
Bacterial antimicrobial compounds have been used traditionally for numerous reasons, including delaying the spoilage of food material or crops by plant pathogens in agriculture, and extending the shelf life of products in the food industry [12]. Compared to terrestrial bacteria, marine bacteria have many unique secondary metabolites due to their more complex and biologically competitive environment and their unique pressure, temperature, salinity, oxygen, light, and pH conditions. These factors make them a rich source Figure 1. Antibiotics reported from different microorganisms with their target sites. Adapted from: [11].

Bacteria
Bacterial antimicrobial compounds have been used traditionally for numerous reasons, including delaying the spoilage of food material or crops by plant pathogens in agriculture, and extending the shelf life of products in the food industry [12]. Compared to terrestrial bacteria, marine bacteria have many unique secondary metabolites due to their more complex and biologically competitive environment and their unique pressure, temperature, salinity, oxygen, light, and pH conditions. These factors make them a rich source of effective antibiotics.
Many researchers have isolated and identified various antimicrobial compounds from marine bacteria against drug-resistant pathogens [13]. Marinomonas mediterranea, a marine bacterium isolated from the Mediterranean Sea at the Murcia coast has antagonistic activity against Pseudomonas sp. and S. aureus resistance to ceftazidime and meticillin antibiotics, respectively [14]. Ayuningrum et al. [15] isolated isatin from the marine bacterium Pseudoalteromonas rubra TKJD 22 associated with a marine tunicate, which has antibacterial activity against MDR pathogens including MDR E. coli, B. cereus, Micrococcus luteus, and B. megaterium. Ieodoglucomide and ieodoglycolipid isolated from the ethyl acetate extract of a marine-derived Bacillus licheniformis bears antifungal activity against the plant pathogens Colletotrichum acutatum and Botrytis cinerea, along with the human pathogen Candid albicans [16]. Similarly, janthinopolyenemycin A and B polyketides were isolated from the proteobacterium Janthinobacterium spp., strains ZZ145 and ZZ148, respectively, by Anjum et al. [17], who found that they hinder the growth of C. albicans. Schulze et al. [18] utilized a genome-assisted discovery strategy to isolate three macrolactams, lobosamides A, B, and C from Micromonospora sp. RL09-050-HVF-A. Among them, lobosamides A and B have antagonist activity against the microbial agent of African trypanosomiasis i.e., Trypanosoma brucei, whereas, lobosamide C has no bioactivity. Zhang et al. [19] reported Streptoseomycin, a macrolactone from the Streptomyces seoulensis A01, having specific activity against microaerophilic bacteria Helicobacter pylori. Bacicyclin, a cyclic peptide, was isolated from a Bacillus sp. strain BC028 associated with mussel (Mytilus edulis), it was found that it inhibits the growth of Enterococcus faecalis and S. aureus with minimal inhibitory concentration (MIC) values of 8 and 12 µM, respectively. In addition, it is used to design analogs with increased antibiotic efficacy [20].

Ribosomally Synthesized Antimicrobial Peptides (Bacteriocins) and Bacteriocin-Like Inhibitory Substances (BLIS)
Bacteriocins are antimicrobial ribosomal peptides reported from all major lineages of bacteria and some members of archaea. Gram-negative intestinal bacteria Escherichia coli produces bacteriocidal proteins, colicins, larger than 20 kDa which are antagonistic against zoonotic strains and might establish a defence line against multidrug-resistant strains. [23]. Bacteriocins have attracted increasing attention because of their use as a food preservative and therapeutic antibiotic. Furthermore, they have also received attention because they have a rapid-acting mechanism by forming pores in the membrane of target bacterial cells, even at very low concentrations ( Figure 2). The recently reported bacteriocins along with their characteristics are presented in Table 1.
Hoyt et al. [24] isolated the first marine bacteriocin from Vibrio harveyi after screening 795 strains of Vibrio sp. from Galveston Island (Texas, USA). This laid the foundation for multiple studies focused on the identification and biochemical characterization of new bacteriocins and bacteriocin-like compounds. Genera of marine bacteria producing bacteriocins include Aeromonas, Bacillus, Burkholderia, Lactococcus, Pseudomonas, Photobacterium, Pediococcus, Enterococcus, Stenotrophomonas, Carnobacterium, Pseudoalteromonas, Streptomyces, etc. The major difference between marine and terrestrial bacteriocins is that marine bacteri- forming pore [30,35] IIc N-and C-termini are covalently linked, generating a circular bacteriocin Lactocyclicin Q, Leucocyclicin Q L. gasseri, Enterococcusfaecalis, L. garvieae

Membrane permeabilization
forming pore [36] Biomolecules 2021, 11, 1860 5 of 28 Disrupt membrane potential, which causes ATP efflux [40] Unfortunately, many factors cause a reduction in BLIS antimicrobial activity affecting the efficacy of bacteriocins. Such factors include the advent of bacteriocin-resistant strains, conditions that are destabilizing its biological activities such as oxidation processes, poor solubility, proteases or inactivation by other additives, and pH or temperature. Therefore, it is necessary to develop an antimicrobial system that minimizes these drawbacks and maximizes bacteriocins' bioprotective potential.
Nisin belongs to type I bacteriocin and is the first antimicrobial peptide from Lactococcus and Streptococcus sp., it has been regarded as GRAS by both the FDA and the WHO [41]. Nisin has been used to inhibit microbial growth in beef, ground beef, sausages, liquid whole eggs, and poultry. It was reported that when nisin was crosslinked to chitosan, minimum inhibitory concentration (MIC) decreased from 48 µg/mL to 40 µg/mL for Staphylococcus aureus ATCC6538. The antimicrobial activity of nisin increased after crosslinking with a lesser concentration of chitosan i.e., the ratio of 200:1, thereby allowing better penetration into the lipid membrane [42]. The antibacterial constancy of nisin was successfully enhanced after its conjugation with gellan. Therefore, this conjugate can be an encouraging biomaterial for wound dressings and transplant coatings [43]. A study revealed the proficiency of nisin in combination with polymyxin in combating P. aeruginosa biofilms and reducing the dose of polymyxin required to interrupt P. aeruginosa biofilms [44]. Polymyxin might facilitate the transfer of nisin to its target. Along with nisin's synergistic action with polymyxin and clarithromycin against P. aeruginosa and other non-β-lactam antibiotics against MRSA [45] and strains of vancomycin-resistant enterococci [46] were also reported. Webber et al. [47] embedded 0.89 µg cm −2 of positively charged nisin Z within polyelectrolyte multilayers (PEMs) i.e., nine layers of carrageenan (CAR) and chitosan (CS), forming a 4.5 bilayer film with antimicrobial activity against S. aureus and MRSA. Therefore, the antimicrobial potential of CAR/CS multilayers helps to realize its applicability within food, pharmaceutical, and biomedical industries [47]. Although nisin has a broad range of biomedical applications and is used in food bio preservation, further justification of nisin's practicality and evaluation of its efficacy in biomedical fields will require in vivo and in vitro studies.
The mechanism of action of bacteriocins depends on the bacteriocin receptor molecules used. All bacteriocins from the same class do not follow a similar mode of action. Bacteriocins might utilize the same receptors but their mode of interaction with these receptor molecules and the aftereffect on the target cell could be quite different. For example, as described by Kjos et al. [48], bacteriocins lactococcin A and lactococcin Z share 55.6% similarity in the N-terminal region, both use IIC and IID components of mannose phospho-transferase system (man-PTS) as receptor molecules on target cells. As depicted in Figure 2, lactococcin A results in pore formation and dissipates the cell membrane potential, whereas lactococcin Z kills target cells without following any of these mechanisms. Lozo et al. [49] comprehensively represented the bacteriocins classification-based receptor molecules in target cells according to structural similarity within the same receptor molecule.
require in vivo and in vitro studies.
The mechanism of action of bacteriocins depends on the bacteriocin receptor molecules used. All bacteriocins from the same class do not follow a similar mode of action. Bacteriocins might utilize the same receptors but their mode of interaction with these receptor molecules and the aftereffect on the target cell could be quite different. For example, as described by Kjos et al. [48], bacteriocins lactococcin A and lactococcin Z share 55.6% similarity in the N-terminal region, both use IIC and IID components of mannose phosphotransferase system (man-PTS) as receptor molecules on target cells. As depicted in Figure 2, lactococcin A results in pore formation and dissipates the cell membrane potential, whereas lactococcin Z kills target cells without following any of these mechanisms. Lozo et al. [49] comprehensively represented the bacteriocins classification-based receptor molecules in target cells according to structural similarity within the same receptor molecule.

Figure 2.
Mode of action of bacteriocins. Inhibition of cell wall synthesis: class II bacteriocins (e.g., lactococcin) cross the cell wall and bind with the pore-forming receptor in the mannose-phosphotransferase (man-PTS), resulting in the pore formation in the cell membrane. Pore formation: class I bacteriocins, (e.g., nisin) can follow both mechanisms. Nisin generated pores in the cell membrane resulting in the efflux of ions (K + and Mg 2+ ), amino acids (glutamic acid, lysin), generating proton motive force dissipation and ultimately causes cell death. Adapted from: [50,51].
Class I bacteriocins are cationic lantibiotics (e.g., nisin) that electrostatically bind with the negatively charged membrane phospholipids II, allowing further interaction of bacte-riocin′s hydrophobic domain with the target cytoplasmic membrane (lipid II), thereby preventing the biosynthesis of peptidoglycan [30,52]. Similarly, class III bacteriocins, enterolysin A with N-terminal endopeptidase domain and a C-terminal substrate Figure 2. Mode of action of bacteriocins. Inhibition of cell wall synthesis: class II bacteriocins (e.g., lactococcin) cross the cell wall and bind with the pore-forming receptor in the mannosephosphotransferase (man-PTS), resulting in the pore formation in the cell membrane. Pore formation: class I bacteriocins, (e.g., nisin) can follow both mechanisms. Nisin generated pores in the cell membrane resulting in the efflux of ions (K + and Mg 2+ ), amino acids (glutamic acid, lysin), generating proton motive force dissipation and ultimately causes cell death. Adapted from: [50,51].
Class I bacteriocins are cationic lantibiotics (e.g., nisin) that electrostatically bind with the negatively charged membrane phospholipids II, allowing further interaction of bacteriocin s hydrophobic domain with the target cytoplasmic membrane (lipid II), thereby preventing the biosynthesis of peptidoglycan [30,52]. Similarly, class III bacteriocins, enterolysin A with N-terminal endopeptidase domain and a C-terminal substrate recognition domain, exhibit antimicrobial activity against streptococci by cleaving the peptidoglycan cross-links between l-alanine and d-glutamic acid of the stem peptide and between l-lysine of the stem peptide and d-aspartic acid of the interpeptide bridge of the target cell [53].

Non-Ribosomal Synthesized Peptides (NRPs) and Polyketides (PKs)
NRPs and PKs include a range of cyclic, linear, and branched compounds, synthesized by composite enzymes viz. non-ribosomal peptide synthetases (NRPS), polyketide synthetases (PKS), and hybrid of NRPS/PKS, respectively [22,54]. Lipopeptides (LPs) are NRPs produced by Bacillales; LPs have significant antimicrobial activity [55]. LAB is considered the primary producer of ribosomally synthesized antimicrobial peptides, as reviewed by Alvarez-Sieiro et al. [53] and Pircalabioru et al. [30]. However, the classification scheme for antimicrobial compounds produced by Bacillus is not explored in comparison to LAB. Caulier et al. [22] reviewed and updated the antimicrobial metabolites classification from the B. subtilis group based on biosynthetic pathway and chemical nature. Zhao et al. [21] acknowledged 31 types of PKs, NRPs, and NRPS/PKS hybrid synthesized antimicrobials using antiSMASH.

Lipopeptides (LPs)
LPs occur naturally and are of bacterial origin, contain a hydrophobic long alkyl chain that associates with a hydrophilic polypeptide, and they form a cyclic or linear structure.
Traditional LPs including the iturins, surfactins, and fengycins (Table 2) produced from Bacillus species are homologs that differ in length, branching pattern, and saturation of their acyl chain. LPs comprise anionic (e.g., surfactin and daptomycin) or cationic (e.g., colistin and polymixin B) peptide motif, dictating the range of their activity. As demonstrated by Perez et al. [56] Bacillus sp. P5 synthesize LPs iturin A, bacteriocin subtilosin A, and surfactin exhibiting antimicrobial activity against L. monocytogenes and B. cereus, along with the antifungal activity. A study by Kourmentza et al. [57] reported that a mixture of mycosubtilin and mycosubtilin/surfactin LPs inhibit the growth of filamentous fungi Byssochlamys fulva and Paecilomyces variotti, with MICs of 1-16 mg/L and Candida krusei with MIC of 16-64 mg/L. .03 kDa et al. [21] acknowledged 31 types of PKs, NRPs, and NRPS/PKS hybrid synthesized antimicrobials using antiSMASH.

Lipopeptides (LPs)
LPs occur naturally and are of bacterial origin, contain a hydrophobic long alkyl chain that associates with a hydrophilic polypeptide, and they form a cyclic or linear structure. Traditional LPs including the iturins, surfactins, and fengycins (Table 2) produced from Bacillus species are homologs that differ in length, branching pattern, and saturation of their acyl chain. LPs comprise anionic (e.g., surfactin and daptomycin) or cationic (e.g., colistin and polymixin B) peptide motif, dictating the range of their activity. As demonstrated by Perez et al. [56] Bacillus sp. P5 synthesize LPs iturin A, bacteriocin subtilosin A, and surfactin exhibiting antimicrobial activity against L. monocytogenes and B. cereus, along with the antifungal activity. A study by Kourmentza et al. [57] reported that a mixture of mycosubtilin and mycosubtilin/surfactin LPs inhibit the growth of filamentous fungi Byssochlamys fulva and Paecilomyces variotti, with MICs of 1-16 mg/L and Candida krusei with MIC of 16-64 mg/L. Surfactins, a cyclic heptapeptide that formulates a lactone bridge with β-hydroxy fatty acids, are the most potent biosurfactant. They display an array of activities including hemolytic, antiviral, anti-mycoplasma, and antibacterial [61]. Surfactin WH1 fungin from Bacillus amyloliquefaciens WH1 is an antifungal inhibiting glucan synthase that reduces the synthesis of callose on the fungal cell wall and binds to ATPase on the mitochondrial membrane, ultimately inducing apoptotic markers to stimulate the extracellular apoptotic pathway [62]. Many researchers claim that after inserting into the lipid bilayers, surfactin acts by forming voltage-independent channels in biofilms, distorting the membrane integrity and permeability of ions, i.e., K + and Ca 2+ , causing membrane disruption [63]. Surfactins, a cyclic heptapeptide that formulates a lactone bridge with β-hydroxy fatty acids, are the most potent biosurfactant. They display an array of activities including hemolytic, antiviral, anti-mycoplasma, and antibacterial [61]. Surfactin WH1 fungin from Bacillus amyloliquefaciens WH1 is an antifungal inhibiting glucan synthase that reduces the synthesis of callose on the fungal cell wall and binds to ATPase on the mitochondrial membrane, ultimately inducing apoptotic markers to stimulate the extracellular apoptotic pathway [62]. Many researchers claim that after inserting into the lipid bilayers, surfactin acts by forming voltage-independent channels in biofilms, distorting the membrane integrity and permeability of ions, i.e., K + and Ca 2+ , causing membrane disruption [63].
Iturins are comprised of A, C, D, and E isoforms, bacillomycin D, F and L, and mycosubtilin that inhibit bacterial growth in the same manner as class I and class II bacteri-

B. subtilis
Act as bioagents showing hypocholesterolemic activities, immunomodulators; antibiotics, antiviral, and antitumor agents; toxins; and enzyme inhibitors [60] Surfactins, a cyclic heptapeptide that formulates a lactone bridge with β-hydroxy fatty acids, are the most potent biosurfactant. They display an array of activities including hemolytic, antiviral, anti-mycoplasma, and antibacterial [61]. Surfactin WH1 fungin from Bacillus amyloliquefaciens WH1 is an antifungal inhibiting glucan synthase that reduces the synthesis of callose on the fungal cell wall and binds to ATPase on the mitochondrial membrane, ultimately inducing apoptotic markers to stimulate the extracellular apoptotic pathway [62]. Many researchers claim that after inserting into the lipid bilayers, surfactin acts by forming voltage-independent channels in biofilms, distorting the membrane integrity and permeability of ions, i.e., K + and Ca 2+ , causing membrane disruption [63].
Iturins are comprised of A, C, D, and E isoforms, bacillomycin D, F and L, and mycosubtilin that inhibit bacterial growth in the same manner as class I and class II bacteriocins [64]. A marine-derived Bacillus velezensis 11-5 produced a cyclic lipopeptide (CLP) iturin A, which is considered an antagonist against Magnaporthe oryzae, a rice pathogen [65]. Fengycin, an anti-fungal lipopeptide, isolated from Bacillus sp. is also called plipastatin. Both iturins and fengycins act as biocontrol agents preventing plant diseases and inhibiting the progression of a wide variety of plant fungal pathogens including Aspergillus flavus, Rhizoctonia solani, Fusarium graminearum, Botritis cinerea, and Penicillium expansum [66]. However, there is no doubt that LPs are a novel class of antibiotics exhibiting a wide range of activities. Therefore, detailed structural and functional knowledge is required to exploit them as potent antimicrobials, feed additives, and drug delivery systems.

Actinomycetes
Approximately 75% of the known industrial antibiotics and economically important compounds were obtained from the Streptomyces species [67]. Actinomycetes can synthesize antifungal, antiviral, antitumor, anti-inflammatory, antioxidants, immunosuppressive, plant-growth-promoting, and herbicidal compounds [68]. Among actinomycetes, Streptomyces is the most dominant because of a broad range of bioactive metabolites. Genus Streptomyces is classified into the family Streptomycetaceae based on its morphology and cell wall chemotype. Streptomyces spp. have filamentous hyphae, allowing them to efficiently utilize nutrients in the rhizosphere, enabling them to colonize and carry out a complex life cycle. Streptomyces spp. catabolizes complex molecules and substances, such as cellulose, lignocellulose, xylan, lignin, etc. to produce well-known bioactive compounds. The genus Streptomyces alone contributes approximately 7500 of the 10,000 known compounds from actinomycetes, whereas the other genera including Actinomadura, Micromonospora, Nocardia, Saccharopolyspora, Actinoplanes and Streptosporangium contribute approximately 2500 compounds [69]. Marine or terrestrial actinomycetes utilize enzymes polyketide synthases (PKS) or non-ribosomal peptide synthetases (NRPS) for the synthesis of metabolic bioactive compounds [70].
Lee et al. [80] isolated 87 actinomycetes species including Streptomyces pluripotens MUSC135T, that inhibit MRSA. This antibacterial metabolite-producing ability was confirmed by PKS (polyketide synthetase) and NRPS (non-ribosomal polyketide synthetase) gene detection process. Streptomyces sp. colonizing on root tissues produce ample antifungal and antibacterial compounds i.e., antimycin A18, phaeochromycin B, C and E, diastaphenazine, 3-acetonylidene-7-prenylindolin-2-one, and staurosporine, some of which are represented in Table 3. Similarly, Jaroszewicz et al. [81] isolated Streptomyces sp. M4_24 and M5_8 strains and identified the presence of dichloranthrabenzoxocinone and 4,10-or 10,12-dichloro-3-O-methylanthrabenzoxocinone, which are putative antimicrobial compounds. A newly discovered lipopeptide NRPS/PKS-derived colibrimycins, from Streptomyces sp. CS147, isolated from Attini ant niche displayed antagonism against virus protease [82]. An endophytic actinomycetes, VITGV01, isolated from a farm tomato plant produced different antibiotics on different media which were active against Gram-positive and Gram-negative bacteria including B. subtilis, S. aureus, E. coli, and Klebsiella pneumoniae [83]. The unique properties of rhizospheric actinomycetes which allow them to produce a diverse range of bioactive metabolites with antagonistic outcomes toward pathogens have led them to be a potent agent ensuring plant health.
Cycloserin, an antibiotic produced by Streptomyces orchidaceus, blocks protein synthesis and is used to treat tuberculosis in conjunction with other drugs [84]. Robertsen and Musiol-Kroll [85] reviewed the actinomycetes-derived polyketide drugs, such as erythromycin A, tetracyclines, rifamycin, tylosin, monensin A, amphotericin B, etc. with antimicrobial activity, including the source of the compounds, their structure, the biosynthetic mechanisms, and mode of action. However, the increasing rate of MDR requires the rediscovery of compounds from potential producers. However, many organisms require special cultivation conditions, therefore, many strategies need to be developed in order to overcome such barriers. Hug et al. [86] described the strategies and innovative methods such as advanced cultivation methods, genomics, metabolomics, and metagenomics-based approaches used to explore the new reservoir of actinomycetes and improve the efficacy of antimicrobial compounds. Hence, it was concluded that Streptomyces spp. can be used as a promising candidate with the potential to be scaled up for industrial production, which could benefit both the agricultural and pharmaceutical industry. Streptomyces sp. neau-D50 Glycine max such as advanced cultivation methods, genomics, metabolomics, and metagenomicsbased approaches used to explore the new reservoir of actinomycetes and improve the efficacy of antimicrobial compounds. Hence, it was concluded that Streptomyces spp. can be used as a promising candidate with the potential to be scaled up for industrial production, which could benefit both the agricultural and pharmaceutical industry. Streptomyces sp. YIM67086 Dysophylla stellata 4-hydroxy-3-methoxybenzoic acid, p--Antifungal activity [78] Cytotoxic and antifungal activities [74] Streptomyces sp. YIM56209

Drymaria cordata
Bafilomycin D, B1, B2, C1, C2, C1 amide and C2 amide based approaches used to explore the new reservoir of actinomycetes and improve the efficacy of antimicrobial compounds. Hence, it was concluded that Streptomyces spp. can be used as a promising candidate with the potential to be scaled up for industrial production, which could benefit both the agricultural and pharmaceutical industry.

Archaea
Archaeocins, is a proteinaceous antibiotic produced from archaea which mark the chronicled beginning in the series of antimicrobial compounds. The term "archaeocin" was used to differentiate the archaeal peptide and protein-based antibiotics from those produced by bacteria [95]. Only two phylogenetic groups have produced archaeocins (Table 4); one is euryarchaeal producing "halocins", whereas the other group is crenarchaeal genus Sulfolobus producing "sulfolobicin" [96]. Valera et al. [97] reported halocins, the first proteinaceous antimicrobial compound from halophilic members of the archaeal domain. Archaeal protein VLL-28, from Sulfolobus islandicus, is the first archaeal antimicrobial peptide, possessing a broad-spectrum antibacterial and antifungal activity [98]. Until recently, very few reports were available on the characterization of antimicrobial compounds from archaea. Besse et al. [99] comprehensively reviewed the archaeocins and sul-Antibacterial, antifungal and anticancer activity [90] Streptomyces sp. YIM66017

Archaea
Archaeocins, is a proteinaceous antibiotic produced from archaea which mark the chronicled beginning in the series of antimicrobial compounds. The term "archaeocin" was used to differentiate the archaeal peptide and protein-based antibiotics from those produced by bacteria [95]. Only two phylogenetic groups have produced archaeocins (Table 4); one is euryarchaeal producing "halocins", whereas the other group is crenarchaeal genus Sulfolobus producing "sulfolobicin" [96]. Valera et al. [97] reported halocins, the first proteinaceous antimicrobial compound from halophilic members of the archaeal domain. Archaeal protein VLL-28, from Sulfolobus islandicus, is the first archaeal antimicrobial peptide, possessing a broad-spectrum antibacterial and antifungal activity [98]. Until recently, very few reports were available on the characterization of antimicrobial compounds from archaea. Besse et al. [99] comprehensively reviewed the archaeocins and sulfolobicins antimicrobial peptides ribosomally-synthesized by archaea belonging to the order Halobacteriales and Sulfolobales, respectively. However, until recently halocin A4,

Archaea
Archaeocins, is a proteinaceous antibiotic produced from archaea which mark the chronicled beginning in the series of antimicrobial compounds. The term "archaeocin" was used to differentiate the archaeal peptide and protein-based antibiotics from those produced by bacteria [95]. Only two phylogenetic groups have produced archaeocins (Table 4); one is euryarchaeal producing "halocins", whereas the other group is crenarchaeal genus Sulfolobus producing "sulfolobicin" [96]. Valera et al. [97] reported halocins, the first proteinaceous antimicrobial compound from halophilic members of the archaeal domain. Archaeal protein VLL-28, from Sulfolobus islandicus, is the first archaeal antimicrobial peptide, possessing a broad-spectrum antibacterial and antifungal activity [98]. Until recently, very few reports were available on the characterization of antimicrobial compounds from archaea. Besse et al. [99] comprehensively reviewed the archaeocins and sulfolobicins antimicrobial peptides ribosomally-synthesized by archaea belonging to the order Halobacteriales and Sulfolobales, respectively. However, until recently halocin A4, G1, R1, H1 [

Archaea
Archaeocins, is a proteinaceous antibiotic produced from archaea which mark the chronicled beginning in the series of antimicrobial compounds. The term "archaeocin" was used to differentiate the archaeal peptide and protein-based antibiotics from those produced by bacteria [95]. Only two phylogenetic groups have produced archaeocins (Table 4); one is euryarchaeal producing "halocins", whereas the other group is crenarchaeal genus Sulfolobus producing "sulfolobicin" [96]. Valera et al. [97] reported halocins, the first proteinaceous antimicrobial compound from halophilic members of the archaeal domain. Archaeal protein VLL-28, from Sulfolobus islandicus, is the first archaeal antimicrobial peptide, possessing a broad-spectrum antibacterial and antifungal activity [98]. Until recently, very few reports were available on the characterization of antimicrobial compounds from archaea. Besse et al. [99] comprehensively reviewed the archaeocins and sulfolobicins antimicrobial peptides ribosomally-synthesized by archaea belonging to the order Halobacteriales and Sulfolobales, respectively. However, until recently halocin A4, G1, R1, H1 [100]; H2 [37]; H3, H5 [97]; H4 [101]; H6 [102]; C8 [103]; S8 [104]; HalR1 [105]; and Sech7a [106] have been considered up to their molecular level, however, their mode of action is not yet clearly understood [107]. Only some workers reported that halocins kill the indicator organisms by altering the cell permeability at membrane level followed by cell lysis. However, to date, only the mode of action mechanism of halocin H6/H7 produced by Haloferax gibbonsii was characterized. HalH6 specifically inhibits Na + /H + antiporter and proton flux ultimately causing cell lysis and death [108].
H1 and H4 are proteinaceous halocins of roughly 30-40 kDa [109], whereas C8, H6, H7, R1, U1, and S8 are microhalocins which are smaller than 10kDa. Microhalocins are more vigorous than proteinaceous halocins since they are resistant to varying temperature, salinity, exposure to organic solvents, acids, and bases [109]. Halocins have wide-ranging activity against haloarchaea and members of the family Halobacteriaceae [110]. Mainly halocin production is prompted during the progression between exponential and stationary phases, with H1 being an exception, produced during the exponential phase of the growth cycle [111]. Recently, Sahli et al. [112] screened 81 halophilic strains collected from solar salterns of Algeria's northern coast for the production of antimicrobial compounds, through partial 16S rRNA gene sequencing, these strains were recognized to belong to the Haloferax (Hfx) sp. Roscetto et al. [117] reported that VLL-28 damages the cell wall of Candida albicans and C. parapsilosis by binding to their cell surface. Kumar and Tiwari [118] purified halocin HA1 from Haloferax larsenii HA1 and HA3 from H. larsenii HA3; both were halocidal against H. larsenii HA10, instigating cellular distortion, releasing cell contents, and finally causing cell death. Because of these properties, it can be used for the preservation of leather hides and salted foods in the leather and food industries. Ghanmi et al. [114] isolated Halobacterium salinarum ETD5, H. salinarum ETD8, and Haloterrigena thermotolerans SS1R12 of the order Halobacteriales and reported that their antimicrobial activity is due to the production of a halocin, HalS8, a hydrophobic peptide. Quadri et al. [119] isolated archeal strain, Natrinema gari, the common producer of antimicrobial compounds, which after partial purification and characterization resembles the microhalocin HalC8. Besse et al. [115] confirmed that Natrinema sp. synthesizes Halocin C8, a 7.4 kDa peptide involving the genes halC8.
Although many studies characterized the synthesis of halocins, the research concerning their structure and mode of action is still far behind in comparison to the antibiotics produced by other domains. Nowadays, when archaea gain more attention, it becomes necessary to explore their metabolites', biosynthetic pathways, mode of action, etc., using the latest available technology.

Fungi
In 1929, Alexander Fleming discovered the mold juice 'Penicillin' from Penicillium notatum fungus with an antibacterial activity [120]. Afterwards, several researchers started to search for a better strain to attain higher yields in easier growth conditions. After extensive research, Penicillium chrysogenum strains were considered for the commercial production of penicillin [121]. Revilla reported in 1986 the formation of the intermediate isopenicillin N in the course of penicillin G production in P. chrysogenum cultures [122], thereafter the formation of isopenicillin N/penicillin N and its late transformation to cephalosporin C in Acremonium chrysogenum [123]. Cephalosporins, a known antimicrobial agent, were purified from a marine fungus, Cephalosporium acremonium [124]. Recently, Li et al. [125] reported that pneumocandins, a lipohexapeptides of the echinocandin family, were produced by wild-type fungi Glarea lozoyensis and Pezicula (Cryptosporiopsis) species. Pneumocandins non-competitively bind to a catalytic unit of β-1,3-glucan synthase, resulting in osmotic uncertainty and cell lysis.

Endophytic Fungi
Huang et al. [126] discovered ten-membered lactones from endophytic fungus Phomopsis sp. YM 311483, with antifungal activity against Aspergillus niger, Fusarium, and Botrytis cinere. Endophytic Fusarium sp. from Selaginella pollescens collected from the Guanacaste conservation area of Costa Rica inhibit C. albicans [127]. The number of antimicrobial compounds were reported from the endophytic fungi, some of which are listed in Table 5. produced by other domains. Nowadays, when archaea gain more attention, it becomes necessary to explore their metabolites', biosynthetic pathways, mode of action, etc., using the latest available technology.

Fungi
In 1929, Alexander Fleming discovered the mold juice 'Penicillin' from Penicillium notatum fungus with an antibacterial activity [120]. Afterwards, several researchers started to search for a better strain to attain higher yields in easier growth conditions. After extensive research, Penicillium chrysogenum strains were considered for the commercial production of penicillin [121]. Revilla reported in 1986 the formation of the intermediate isopenicillin N in the course of penicillin G production in P. chrysogenum cultures [122], thereafter the formation of isopenicillin N/penicillin N and its late transformation to cephalosporin C in Acremonium chrysogenum [123]. Cephalosporins, a known antimicrobial agent, were purified from a marine fungus, Cephalosporium acremonium [124]. Recently, Li et al. [125] reported that pneumocandins, a lipohexapeptides of the echinocandin family, were produced by wild-type fungi Glarea lozoyensis and Pezicula (Cryptosporiopsis) species. Pneumocandins non-competitively bind to a catalytic unit of β-1,3-glucan synthase, resulting in osmotic uncertainty and cell lysis.

Endophytic Fungi
Huang et al. [126] discovered ten-membered lactones from endophytic fungus Phomopsis sp. YM 311483, with antifungal activity against Aspergillus niger, Fusarium, and Botrytis cinere. Endophytic Fusarium sp. from Selaginella pollescens collected from the Guanacaste conservation area of Costa Rica inhibit C. albicans [127]. The number of antimicrobial compounds were reported from the endophytic fungi, some of which are listed in Table  5. produced by other domains. Nowadays, when archaea gain more attention, it becomes necessary to explore their metabolites', biosynthetic pathways, mode of action, etc., using the latest available technology.

Fungi
In 1929, Alexander Fleming discovered the mold juice 'Penicillin' from Penicillium notatum fungus with an antibacterial activity [120]. Afterwards, several researchers started to search for a better strain to attain higher yields in easier growth conditions. After extensive research, Penicillium chrysogenum strains were considered for the commercial production of penicillin [121]. Revilla reported in 1986 the formation of the intermediate isopenicillin N in the course of penicillin G production in P. chrysogenum cultures [122], thereafter the formation of isopenicillin N/penicillin N and its late transformation to cephalosporin C in Acremonium chrysogenum [123]. Cephalosporins, a known antimicrobial agent, were purified from a marine fungus, Cephalosporium acremonium [124]. Recently, Li et al. [125] reported that pneumocandins, a lipohexapeptides of the echinocandin family, were produced by wild-type fungi Glarea lozoyensis and Pezicula (Cryptosporiopsis) species. Pneumocandins non-competitively bind to a catalytic unit of β-1,3-glucan synthase, resulting in osmotic uncertainty and cell lysis.

Endophytic Fungi
Huang et al. [126] discovered ten-membered lactones from endophytic fungus Phomopsis sp. YM 311483, with antifungal activity against Aspergillus niger, Fusarium, and Botrytis cinere. Endophytic Fusarium sp. from Selaginella pollescens collected from the Guanacaste conservation area of Costa Rica inhibit C. albicans [127]. The number of antimicrobial compounds were reported from the endophytic fungi, some of which are listed in Table  5.

Marine-Derived Fungi
In 2015 Meng et al. [133] discovered pyranonigrin F from fungus Penicillium brocae MA-231 allied with the Avicennia marina, a marine mangrove plant. Pyranonigrin F inhibits S. aureus (Gram-positive), Vibrio harveyi, and Vibrio parahemolyticus (Gram-negative bacteria), with considerably lower MIC values in comparison to the positive control (chloromycetin). Likewise, it is active against plant fungal pathogens Alternaria brassicae and Colletotrichum gloeosprioides, with improved MIC values compared to the positive control (bleomycin). Wu et al. [134] discovered Lindgomycin from Lindgomyces strains LF327 and KF970, reported from a sponge in the Baltic Sea, Germany, and Antarctica, respectively. Lindgomycin displayed antimicrobial activity against S. aureus, S. epidermidis, and methicillin-resistant S. epidermidis (MRSE). However, the inhibiting potential was two times less than the positive control chloramphenicol. It also constrains plant pathogenic bacterium Xanthomonas campestris. There is a never-ending list of antimicrobial compounds from marine fungi; a few of which are listed in Table 6, which displays their host, producer species, and bioactivity.

Marine-Derived Fungi
In 2015 Meng et al. [133] discovered pyranonigrin F from fungus Penicillium brocae MA-231 allied with the Avicennia marina, a marine mangrove plant. Pyranonigrin F inhibits S. aureus (Gram-positive), Vibrio harveyi, and Vibrio parahemolyticus (Gram-negative bacteria), with considerably lower MIC values in comparison to the positive control (chloromycetin). Likewise, it is active against plant fungal pathogens Alternaria brassicae and Colletotrichum gloeosprioides, with improved MIC values compared to the positive control (bleomycin). Wu et al. [134] discovered Lindgomycin from Lindgomyces strains LF327 and KF970, reported from a sponge in the Baltic Sea, Germany, and Antarctica, respectively. Lindgomycin displayed antimicrobial activity against S. aureus, S. epidermidis, and methicillin-resistant S. epidermidis (MRSE). However, the inhibiting potential was two times less than the positive control chloramphenicol. It also constrains plant pathogenic bacterium Xanthomonas campestris. There is a never-ending list of antimicrobial compounds from marine fungi; a few of which are listed in Table 6, which displays their host, producer species, and bioactivity.

Marine-Derived Fungi
In 2015 Meng et al. [133] discovered pyranonigrin F from fungus Penicillium brocae MA-231 allied with the Avicennia marina, a marine mangrove plant. Pyranonigrin F inhibits S. aureus (Gram-positive), Vibrio harveyi, and Vibrio parahemolyticus (Gram-negative bacteria), with considerably lower MIC values in comparison to the positive control (chloromycetin). Likewise, it is active against plant fungal pathogens Alternaria brassicae and Colletotrichum gloeosprioides, with improved MIC values compared to the positive control (bleomycin). Wu et al. [134] discovered Lindgomycin from Lindgomyces strains LF327 and KF970, reported from a sponge in the Baltic Sea, Germany, and Antarctica, respectively. Lindgomycin displayed antimicrobial activity against S. aureus, S. epidermidis, and methicillin-resistant S. epidermidis (MRSE). However, the inhibiting potential was two times less than the positive control chloramphenicol. It also constrains plant pathogenic bacterium Xanthomonas campestris. There is a never-ending list of antimicrobial compounds from marine fungi; a few of which are listed in Table 6, which displays their host, producer species, and bioactivity.

Marine-Derived Fungi
In 2015 Meng et al. [133] discovered pyranonigrin F from fungus Penicillium brocae MA-231 allied with the Avicennia marina, a marine mangrove plant. Pyranonigrin F inhibits S. aureus (Gram-positive), Vibrio harveyi, and Vibrio parahemolyticus (Gram-negative bacteria), with considerably lower MIC values in comparison to the positive control (chloromycetin). Likewise, it is active against plant fungal pathogens Alternaria brassicae and Colletotrichum gloeosprioides, with improved MIC values compared to the positive control (bleomycin). Wu et al. [134] discovered Lindgomycin from Lindgomyces strains LF327 and KF970, reported from a sponge in the Baltic Sea, Germany, and Antarctica, respectively. Lindgomycin displayed antimicrobial activity against S. aureus, S. epidermidis, and methicillin-resistant S. epidermidis (MRSE). However, the inhibiting potential was two times less than the positive control chloramphenicol. It also constrains plant pathogenic bacterium Xanthomonas campestris. There is a never-ending list of antimicrobial compounds from marine fungi; a few of which are listed in Table 6, which displays their host, producer species, and bioactivity.

Marine-Derived Fungi
In 2015 Meng et al. [133] discovered pyranonigrin F from fungus Penicillium brocae MA-231 allied with the Avicennia marina, a marine mangrove plant. Pyranonigrin F inhibits S. aureus (Gram-positive), Vibrio harveyi, and Vibrio parahemolyticus (Gram-negative bacteria), with considerably lower MIC values in comparison to the positive control (chloromycetin). Likewise, it is active against plant fungal pathogens Alternaria brassicae and Colletotrichum gloeosprioides, with improved MIC values compared to the positive control (bleomycin). Wu et al. [134] discovered Lindgomycin from Lindgomyces strains LF327 and KF970, reported from a sponge in the Baltic Sea, Germany, and Antarctica, respectively. Lindgomycin displayed antimicrobial activity against S. aureus, S. epidermidis, and methicillin-resistant S. epidermidis (MRSE). However, the inhibiting potential was two times less than the positive control chloramphenicol. It also constrains plant pathogenic bacterium Xanthomonas campestris. There is a never-ending list of antimicrobial compounds from marine fungi; a few of which are listed in Table 6, which displays their host, producer species, and bioactivity.

Colletotrichum asianum
Marine sponge Callyspongia sp. [154] Peniciadametizine A and Peniciadametizine B derivative of thiolated diketopiperazine was isolated from sponges-associated Penicillium sp. viz. Penicillium adametzioides AS-53 and Penicillium sp. LS54, respectively. Both derivatives inhibit A. brassicae (pathogenic fungus) with a MIC of 4.0 µg/mL and 32.0 µg/mL, respectively [138]. Communol A, G, and F extracted from P. commune 518 displayed antibacterial activities against E. coli with MIC values of 4.1, 23.8, and 6.4µM, respectively, and also against E. aerogenes [136]. Pyrrospirones were produced by marine-derived fungus Penicillium sp. ZZ380, isolated from Pachygrapsus crassipes which is a wild crab found on the seaside rocks of Putuo Mountain (Zhoushan, China). Pyrrospirones C-F, H, and I inhibit MRSA and E. coli having MIC values of 2.0-19.0 µg/mL [155]. Song et al. [156], following the previous lead, separated penicipyrrodiether A from a cultured marine fungal strain Penicillium sp. ZZ380 which inhibits E. coli and S. aureus with MIC of 34.0 and 5.0 µg/mL, respectively. These laboratory studies need to be directed toward developing the efficiency and effectiveness of isolated compounds that could benefit society in the long-term.

Mushrooms
Mushrooms are colonizing fungi belonging to division Eumycota and subdivision Basidiomycetes, characterized by the formation of basidiospores. Most of these macrofungi are edible, with culinary, nutritional, and medicinal characteristics, but many of them are not palatable or are poisonous [157]. Besides the nutritional and culinary properties, their antimicrobial activities attracted researchers seeking natural solutions to deal with the urgent requirements of food safety. Mushrooms have been publicly consumed for thousands of years due to their medicinal and nutritional properties. Secondary metabolites and extracts from mushrooms have recently attained considerable attention due to their anticancer, antioxidant, anti-inflammatory, antimicrobial, antidiabetic, and immunomodulatory properties. Approximately 1069 mushroom species have been consumed by people [158]. To date, numerous antimicrobial peptides have been acknowledged from mushrooms. Plectasin (endogenous peptide antibiotics), an antibacterial peptide, was extracted from Pseudoplectania nigrella. Mygind et al. [159] demonstrated the potent activity of recombinant plectasin against some Gram-positive Streptococcus pneumoniae. Wong et al. [160] described an antifungal peptide, cordymin isolated from medicinal mushroom Cordyceps militaris, which repressed mycelial growth of Bipolaris maydis, Mycosphaerella arachidicola, Candida albicans, and Rhizoctonia solani with IC 50 values of 50 µM, 10 µM, 0.75 mM, and 80 µM, respectively. They also reported the remarkable pH stability (pH 6-13), thermostability (100 • C), and metal ion stability (10 mM Mg 2+ and 10 mM Zn 2+ ) of cordymin. An investigation by Gebreyohannes et al. [161] revealed that chloroform, ethanol, and hot water extract of Auricularia and Termitomyces sp. promisingly inhibited E. coli, K. pneumoniae, C. parapsilosis, and S. aureus. Poompouang and Suksomtip, [162] isolated an antifungal compound of 17 kDa from fruiting bodies of edible mushroom, Lentinus squarrosulus, inhibiting Trichophyton mentagrophytes and T. rubrum, a human fungal pathogen. More recently, Irshad et al. [163] comprehensively reviewed the synthesis and mode of action of polysaccharides silver nanoparticles (NPs) from Pleurotus mushroom. They characterized the NPs through ultraviolet-visible (UV-Vis), Fourier transformation infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), energy dispersive spectroscopy (EDS), transmission electron microscopy (TEM), etc., and disclosed their promising antimicrobial efficiency. However, further studies are required in order to fortify and test these extracts and NPs against human and plant pathogenic microorganisms coupled with the purification and characterization of the compounds from mushrooms.
Hamamoto et al. [164] screened the volatile compound, 3,4-dichloro-4-methoxy benzaldehyde (DCMB) from mycelia of Porostereum spadiceum. It remarkably inhibited the plant-pathogenic bacteria (Clavibacter michiganensis and Ralstonia solanacearum) and inhibited the conidial germination of plant-pathogenic fungi (Alternaria brassicicola and Colletotrichum orbiculare). However, further studies are essential to investigate its effects on plant-pathogens in vivo. Subrata et al. [165] reported that edible wild mushrooms' methanolic extracts exhibited different levels of antimicrobial activities. A recent study by Sevindi [166] analysed the phenolic content of the wild edible mushroom Melanoleuca melaleuca (Pers.) Murrill had antimicrobial activities inhibiting Gram-negative E. coli, Pseudomonas aeruginosa, and Acinetobacter baumannii.

Filamentous Fungi
Yeasts mainly occur in milk, meat, food, and products such as fruit, yogurt, jams, sausage, and cheeses. Generally, antimicrobial compounds produced from yeasts inhibit the evolution/growth of pathogenic organisms (bacteria or molds) in food products. Some classes of yeasts secrete toxins, thereby naming them killer yeasts. Killer yeasts naturally occur in rotten vegetables and fruits and constrain the growth of other yeast strains and also inhibit microbial growth [167]. Saccharomyces cerevisiae (baker's yeast), unicellular yeast, is the most widely studied microorganisms involved in many biotechnological practices because of its good fermentation capacity [168]. The inhibitory mechanism of S. cerevisiae killer strains was discovered in 1963 by Bevan and co-worker's, and the phenomenon is related to the secretion of a protein toxin, k1, and k28 from the host that kills sensitive target pathogenic cells in a receptor-mediated approach without direct cell-to-cell contact [169]. Other genera producing killer toxins include Cryptococcus, Candida, Kluyveromyces, Williopsis, Pichia, Debaromyces, and Zygosaccharomyces [170]. The anti-bacterial capability of S. cerevisiae is attributed to: Sequential re-pitching of Saccharomyces biomass is a common process during brewing. Therefore, yeast is reused many times before its final dumping [171]. Hence, yeast develops an adaptive response against oxidative stress like that of human cells, leading to the accumulation of vitamins (B6 and B12) and minerals (enzyme co-factors including zinc, manganese, and copper) in the yeast cell. Phenolic compounds are also adsorbed by Saccharomyces from the exterior medium, which increases the phenolic content and antioxidant activity within yeast cells [172]. Efficient means are required to disrupt yeast cell walls and separate the products of interest, which are further used for food applications. However, increasing consumer' fears regarding the toxicity of killer yeast strains present in food and milk products constitutes a direct risk to public health.

Microalgae
The antimicrobial activity of microalgae is due to the presence of phytochemicals, including indoles, acetogenins, terpenes, fatty acids, phenols, and volatile halogenated hydrocarbons (Table 7) [173]. Moreno et al. [174] reported that Chaetoceros muelleri extracts' antimicrobial activity is due to their lipid configuration, whereas Dunaliella salina's is attributed to the presence of β-cyclocitral, α and β-ionone, phytol, and neophytadiene. In natural environmental conditions, microalgal cells release fatty acids against predators and pathogenic bacteria. It is elucidated that these fatty acids act on bacterial cell membranes causing cell seepage, a decline in nutrient intake, and reduced cellular respiration, ultimately resulting in cell death [175]. Chlorellin, the first antibacterial compound from a microalga Chlorella, is composed of a mixture of fatty acid and was isolated by Pratt et al. [183]. Chlorellin was reported to inhibit the activity of both Gram-positive and Gram-negative bacteria. Arthrospira platensis, commercially known as Spirulina had MICs of 0.20% for L. innocua and P. fluorescens, and an MIC of 0.25% for Serratia, whereas minimal bactericidal concentration (MBC) value was 0.30% for all of these species [184]. HPTLC screening and GC-MS analyses were conducted to detect and screen the macroalgae's antimicrobial compounds. Peptides, namely AQ-1756, AQ-1757, and AQ-1766 identified from Tetraselmis suecica exhibited an antibacterial activity resulting in decreasing cell viability (human embryonic kidney cells) (HEK293) up to 75% after 24 h of treatment. AQ-1766 was more active against Gram-positive than Gramnegative bacteria, with MBC values between 40 and 50 µM [185]. Mendiola et al. [186] demonstrated that lipid fractions obtained from Chaetoceros muelleri by the supercritical CO 2 method have antibacterial activity against Staphyloccocus aureus and E. coli. In contrast, extraction via classic methods using hexane, dichloromethane, and methanol solvent did not result in any activity against E. coli. However, these studies were unable to elaborate the mode of action of these antibacterial compounds.
Axenic microalgae co-culture can produce compounds with potent activity against pathogenic bacteria. Kokou et al. [187] reported that axenic cultures of Tetraselmis chui, Chlorella minutissima, Isochrysis sp. and Nannochloropsis sp. inhibit Vibrio harveyi. The potent activity of microalgal compounds against microorganisms requires further development in the search for drugs and food preservatives. Therefore, the exploitation in medicine deserves to be further investigated.

Discussion and Future Prospects
One of the significant challenges healthcare services face worldwide is the excessive use of antibiotics in medicine and food production, leading to microbiome disruption. With the outburst of antimicrobial resistance strains, there is a continuous decline in the antimicrobial drug pipeline, and it has become necessary to discover and develop new agents/metabolites to tackle antibiotic resistance. Novel compounds that target microbial resistance can be developed to regulate the huge risk posed by multi-drug resistance. However, the production cost needs to be reduced by isolating these compounds from natural sources such as microorganisms and then synthesizing them or modifying derivative compounds. Along with this, further research into their toxicity against human cells, their mode of action, in vivo effects, and their interactions with commonly available antibiotics must be conducted. After the discovery of penicillin, many drug discoveries from microbial sources were reported. In addition, the advancement of techniques such as genetic engineering during the 1970s opened the door to the ignored source, i.e., microbial metabolites [188].
Ample research is being conducted to search for novel antimicrobial agents from biological sources, including bacteria, actinomycetes, fungi, yeast, etc. Table 8 depicts selected commercially available antimicrobial products alongside their uses.  [194] LAB producing bacteriocins are a promising candidate for the food industry as they help to extend shelf life and safeguarde consumers' health. Actinomycetes, particularly Streptomyces spp., exhibited effective antagonistic activity and played a significant role in drug discovery and development.
In the ongoing rearch for novel antibiotics, archaeocins have generally been overlooked, and further studies on purifications and characterizations of archaeocins and sulfolobicins are in progress, resulting in the economical production of bioactive compounds for pharmaceutical applications. It is desirable to expand our understanding of the effectiveness and use of other naturally occurring ribosomally-synthesized peptide antimicrobials to understand their implantation and survival strategies, and to quantitatively estimate their efficacy for future applications in the pharmaceutical and health care sectors.
Fungi synthesized small quantities of bioactive compounds in response to explicit environmental conditions which cannot be reproduced easily in the laboratory. Therefore, to develop new antimicrobial drugs from these fungal metabolites, commercial-scale synthesis must be accomplished potentially through strain improvement, optimizing growth conditions, and incorporating techniques, such as metabolomics, genomics, and pathway engineering. Endophytic, filamentous, and marine-derived fungi also offer a suitable substitute against toxic, ineffective, and expensive antimicrobial drugs because they act as a warehouse filled with bioactive compounds with endless potential for biological properties. Antimicrobials, isolated from mushrooms, act as essential substitutes to synthetic drugs and preservatives, whose protection and influence on the health of humans, animals, and food are still uncertain. Although there are many edible mushrooms, the mushroom species identified have antimicrobial properties which are quite small. The current review demonstrates potent bioactive substances with antimicrobial activities from edible mushrooms. Hence, they must not be considered only as a culinary delicacy, but also taken as therapeutic agents. However, methods for isolation, purification, identification, and characterization of antimicrobial compounds from mushrooms need to be developed.
Microalgae are a promising source of high-value products, and large-scale screening programs have been conducted to discover the antimicrobial potential of microalgal extracts against pathogenic and foodborne organisms. However, major antibacterial and antifungal activity reports were predominantly from the Chlorella sp. and Chlamydomonas sp. Many hurdles exist in developing the marine product, including resource supply issues, large-scale production, production cost, and determination of the efficacy target. These obstacles must be bypassed by optimizing mass culturing conditions, utilizing biotechnological techniques, etc. Along with these measures, extensive clinical trials will be needed to determine the in vivo fortune of antimicrobials from microbial extracts on mammalian cells.
Therefore, developing and using robust screening and high-throughput methods will be essential to study their antimicrobial activity, thereby increasing the chances of discovering and identifying new antibiotic molecules. To achieve this goal, the experimental design must include all possible variables, such as recovering both intra-and extracellular extracts produced by microorganisms under variable growth conditions, utilizing potential inducers of antimicrobial activity, and testing these compounds against a more significant number of targets. In recent years, nanoencapsulation has gained much attention. It is a technique used for formulating and stacking a compound in nanosized carriers that can carry and deliver the molecules to the targeted site. Nanoencapsulation allows the conservation and controlled release of bioactive compounds, followed by resistance to pH and temperature variations, lesser product contamination, economic viability, and stability. Chromatographic separation techniques were used recently for purifying antimicrobials, followed by their chemical characterization using spectroscopic techniques, and response surface methodology (RSM) to predict the yield of the crude antimicrobial extract. Detailed functional and structural knowledge would explain antimicrobials' mode of action and performance at cellular and molecular levels. However, for this, a better understanding of the structure, function and, existing mode of action of newly identified antimicrobials is required.

Conclusions
In conclusion, microorganisms are probable sources of bioactive compounds, and this review has explored of microorganisms' aptitudes to deliver novel bioactive compounds with potential pharmaceutical and nutraceutical applications. Microorganisms have fascinated many researchers due to the ease of growth and understanding of their chemical interactions. The development of new biotechnological tools and techniques contributes to the discovery of next-generation antimicrobial compounds. The application of microorganisms in human foods, animal feeds, agriculture, and an increased market demand motivates the research and development of novel antibiotics and preservatives. Furthermore, the molecular docking and structural analysis approaches can design potent pathogen-specific antimicrobial agents that exhibit lesser toxicity, higher selectivity, and biodegradability. Therefore, exploiting microbial biodiversity and biotechnological potential to discover novel bioactive compounds to treat life-threatening diseases and safeguard human health.